H. Lee Moffitt Cancer Center & Research Institute
12902 Magnolia Drive
Tampa
Florida
33612-9497
United States
Tel: 888-663-3488
Website: http://www.moffitt.org/
About H. Lee Moffitt Cancer Center & Research Institute
Moffitt Cancer Center is …
- Dedicated to one mission: to contribute to the prevention and cure of cancer.
- A not-for-profit cancer center created by the Florida Legislature and opened on the campus of the University of South Florida in Tampa in 1986.
- Named after H. Lee Moffitt, former Speaker of the Florida House of Representatives.
- One of only 39 cancer center designated by the National Cancer Institute as a Comprehensive Cancer Center.
- Ranked 13th in the U.S. News & World Report magazine’s “Best Hospitals” list of top cancer centers for 2005
- A critical resource for the state of Florida, which ranks 2nd in the U.S. in both cancer incidence and mortality.
- The site of the Bill & Beverly Young National Functional Genomics Center, funded by the U.S. Department of Defense.
- A major cancer research center with scientific programs in Molecular Oncology; Drug Discovery; Immunology; Experimental Therapeutics; Health Outcomes & Behavior; and Risk Assessment, Detection & Intervention.
- A center for translational research whose researchers and physicians are committed to improving cancer care by moving discoveries quickly from laboratory bench to patient bedside and into the community.
- The recipient of more than $50 million annually in sponsored research awards.
- The largest provider of blood and marrow transplants in the Southeastern U.S.
- A major economic engine that employed 2,655 people and generated $361 million in direct output in 2005.
Moffitt Cancer Center provides …
- Compassionate care through more than 200,000 outpatient visits and 6,000 admissions per year on site.
- Statewide service, impacting 20 percent of cancer cases in Florida through a network of 16 hospital and practice affiliations and more than 400 oncologists.
- Access to clinical trials – with more than 200 ongoing clinical trials encompassing new and established procedures in chemotherapy, surgery, radiation, and immunotherapy.
- Screening and prevention services to more than 20,000 people per year, including genetic screening and counseling; smoking cessation programs; clinics for patients at high risk for cancer; mammography and other tests; and a wide array of community education and outreach programs.
- Comprehensive training, in partnership with the University of South Florida College of Medicine, in all aspects of cancer treatment, research and prevention for medical students, post-graduate fellows, residents, and community physicians.
- Cancer Answers to anyone with a question related to cancer prevention, early detection, diagnosis, treatment and research via 1-888-MOFFITT, a toll-free information line staffed by registered nurses.
Last Updated: 12-27-2006
80 articles about H. Lee Moffitt Cancer Center & Research Institute
-
CancerX Announces Steering Committee and Strategic Priorities
9/12/2023
CancerX, the public-private partnership that launched in March of this year to harness the power of innovation to help achieve the goals of the Cancer Moonshot, announced its inaugural steering committee and strategic priorities.
-
Clario Announces Strategic Partnership Supporting CancerX and White House Cancer Moonshot
6/2/2023
Clario announced it is joining CancerX - a public-private partnership to act as a national accelerator to boost innovation in the fight against cancer.
-
Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial
5/22/2023
Anixa Biosciences, Inc. today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
-
Panbela Announces Clinical Trial with Moffitt Cancer Center for Phase I/II Program in STK11 Mutant Non-Small Cell Lung Cancer
5/22/2023
Panbela Therapeutics, Inc. today announced it has entered into a clinical trial agreement with Moffitt Cancer Center for a Phase I/II program in STK11 mutant non-small cell lung cancer (NSCLC).
-
Memora Health Announces Partnership with Moffitt Cancer Center to Scale Data-Driven Cancer Care
2/23/2023
Memora Health, the leading intelligent platform for virtual care delivery and complex care management, announced a partnership with Moffitt Cancer Center, one of the nation's leading cancer care and research institutions.
-
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
8/15/2022
Anixa Biosciences, Inc. today announced that, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
-
Dr. Amaka Eneanya told BioSpace that kidney disease, which disproportionately affects people of color, has historically been underrepresented in clinical research compared to other areas of medicine.
-
A combination study of CG Oncology’s oncolytic immunotherapy and a checkpoint inhibitor is showing promise.
-
Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma
3/30/2022
Sterotherapeutics, LLC announced today that it has entered into an exclusive agreement with Moffitt Cancer Center and Florida Atlantic University Research Corporation for a license to novel compounds and methods for the treatment of multiple myeloma.
-
Dyve Biosciences Announces Research and Development Collaboration with Moffitt Cancer Center
2/3/2022
Dyve Biosciences, Inc. today announced a joint, two-year research collaboration with Moffitt Cancer Center.
-
Turnstone Biologics Announces Research Collaboration with Moffitt Cancer Center to Advance Novel TIL Immunotherapies for Solid Tumor Indications
11/29/2021
Turnstone Biologics Corp., a clinical-stage biotechnology company pioneering the development of cancer immunotherapies, announced that it has entered into a strategic multi-year research collaboration with Moffitt Cancer Center for pre-clinical development of investigational tumor-infiltrating lymphocyte therapies.
-
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
8/30/2021
Anixa Biosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy
-
Moffitt Named to DiversityInc’s List of Top Hospitals & Health SystemsCancer center climbs to highest-ranking yet on annual list celebrating diversity in business.
5/12/2021
Moffitt Cancer Center is honored to earn the No. 3 position on DiversityInc’s Top Hospitals and Health Systems for 2021.
-
Moffitt Cancer Center Advances Patient Standard of Care by Introducing Needleless Blood DrawsMoffitt is the first cancer center and the first hospital in Florida to use this new technology
3/24/2021
Moffitt Cancer C enter has adopted a new needle-free method of blood collection for patients in treatment who often need to undergo repeated needle sticks in a day, becoming the first cancer center in Florida to offer this pain-free technology as part of its world-class cancer care.
-
Here’s a recap of companies announcing facility expansions this past month and life sciences job creations across the nation.
-
Tampa Bay Buccaneers Defensive End William Gholston Funds Cancer Health Disparities Research at Moffitt Cancer Center
2/1/2021
Moffitt Cancer Center announced that Tampa Bay Buccaneers defensive end William Gholston has donated $225,000 to support research into cancer health disparities.
-
While companies around the globe reduce staff amidst economic upheaval, there's at least one industry on the rise - life sciences. Here's who's breaking ground on expansion projects.
-
AutoNation Donates $62,000 for Moffitt Cancer Center
12/18/2020
AutoNation, Inc. (NYSE: AN), AutoNation, America's largest and most recognized automotive retailer, presented a $62,000 check to Moffitt Cancer Center at Mercedes-Benz of Sarasota on Tuesday, De
-
Through their work, they were able to determine that the protein, TAp63, appears to impact the level of RNA molecules within the body. This subsequently connects the activities of p53 and AKT, the altered genes in cancer.
-
Elicio Therapeutics and Moffitt Collaborate to Study AMP-CD19 in Combination with CD19 CAR T Cells
9/17/2020
Elicio Therapeutics, a next generation immuno-oncology company, announced that it has established a collaboration with the Moffitt Cancer Center to characterize combination therapies pairing Elicio’s CD19 Amphiphile and a universal FITC Amphiphile with CD19 CAR T cells.